Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Highnoon LaboratoriesKAR:HINOON -0.45%96 EBITDA Margin % is 27.36% as of Mar. 2026, which is 38% above its 10-year median of 19.76. GuruFocus rates KAR:HINOON with a GF Score™ of 96/100 and a GF Value™ of ₨1,019.72 (Fairly Valued). The stock has 3 warning signs investors should review. Among 959 Drug Manufacturers companies, Highnoon Laboratories ranks better than 80.29% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Highnoon Laboratories EBITDA Margin % Related Terms
Highnoon Laboratories EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Highnoon Laboratories's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:HINOON vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Highnoon Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Highnoon Laboratories EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Highnoon Laboratories's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Highnoon Laboratories's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Highnoon Laboratories (KAR:HINOON) has a EBITDA Margin % of 27.36% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Highnoon Laboratories and its competitors. This is 38% above median its historical median of 19.76. Over the past decade, Highnoon Laboratories' EBITDA Margin % has ranged from 16.16 to 26.65. According to the industry distribution chart, Highnoon Laboratories ranks #189 out of 959 companies in the Drug Manufacturers industry, placing it in the top 19.7%.
Is Highnoon Laboratories' EBITDA Margin % too high?
Highnoon Laboratories' current EBITDA Margin % of 27.36% is 38% above median its 10-year median of 19.76. Over the past 10 years, this metric has ranged from a low of 16.16 to a high of 26.65. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Highnoon Laboratories' value of 27.36% is 119.1% above this industry median. Based on the distribution chart, Highnoon Laboratories ranks #189 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Highnoon Laboratories has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Highnoon Laboratories' EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Highnoon Laboratories ranks #189 out of 959 companies for EBITDA Margin %. This places Highnoon Laboratories in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.49. Highnoon Laboratories' value of 27.36% is 119.1% above this benchmark. Historically, Highnoon Laboratories' own EBITDA Margin % has ranged from 16.16 to 26.65 over the past decade. While the company's 10-year median is 19.76 vs. the industry median of 12.49, Highnoon Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Highnoon Laboratories's current EBITDA Margin % of 27.36% is 119.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Highnoon Laboratories and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Highnoon Laboratories's current EBITDA Margin % is 27.36%, which is 38% above median its own 10-year median of 19.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Highnoon Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Highnoon Laboratories (KAR:HINOON) is currently considered Fairly Valued. The stock's GF Value™ is ₨1,019.72, compared to a current price of ₨961.21 — trading 5.7% below its estimated fair value. The current EBITDA Margin % is 27.36%, which is 38% above median its 10-year median of 19.76 and 119.1% above the Drug Manufacturers industry median of 12.49. Highnoon Laboratories' overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Highnoon Laboratories (KAR:HINOON), the current EBITDA Margin % is 27.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Highnoon Laboratories (KAR:HINOON) Overvalued in 2026?
Based on GuruFocus' analysis, Highnoon Laboratories stock appears to be undervalued.
The current stock price of ₨961.21 is trading 5.7% below its estimated GF Value™ of ₨1,019.72.
GuruFocus considers Highnoon Laboratories to be Fairly Valued.
Key valuation signals for KAR:HINOON:
EBITDA Margin %: 27.36% (38% above median its 10-year median of 19.76)
GF Value™: ₨1,019.72 vs. price of ₨961.21 (5.7% below fair value)
Industry Position: 119.1% above the Drug Manufacturers median (#189 of 959)
No single metric tells the full story. See the KAR:HINOON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Highnoon Laboratories Ltd is a company engaged in the manufacture, import, sale, and marketing of pharmaceutical and allied consumer products. It focuses on the alimentary tract and metabolism, antihistamines, anti-infectives, cardiovascular, endocrine, hematology, musculoskeletal, nervous system, parasitology, respiratory, and urinary. Its products include AIRTAL (Aceclofenac); ARIA (ketotifen); ARTECXCIN, and artrodar (diacerein). Its other products include Asthavent, AXESOME, Bezisox, Betatec, and many more.
96GF Score
Get the complete analysis for KAR:HINOON
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:HINOON has been successfully added to your 
